Is ALUMIS INC. (ALMS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.9% / 30% | 8.6% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.9% / 33% | 8.6% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 9.0% / 33% | 84.5% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.9% / 33% | 8.6% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 9.0% / 33% | 84.5% / 33% | 0.5% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -5067.1% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -86.7% | |
| Return on Assets (ROA) | -73.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$255M |
| Free Cash Flow | -$257M |
| Total Debt | $31M |
| Debt-to-Equity | 12.3 |
| Current Ratio | 4.3 |
| Total Assets | $341M |
Price & Trading
| Last Close | $26.31 |
| 50-Day MA | $26.52 |
| 200-Day MA | $11.16 |
| Avg Volume | 3.0M |
|
52-Week Range
$2.76
| |
About ALUMIS INC. (ALMS)
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ALUMIS INC. (ALMS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ALUMIS INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ALUMIS INC.'s debt ratio?
ALUMIS INC.'s debt ratio is 0.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 9.0%.
What are ALUMIS INC.'s key financial metrics?
ALUMIS INC. has a market capitalization of $3.2B. Return on equity stands at -86.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.